Biogen
BIIB
948 hedge funds and large institutions have $49.9B invested in Biogen in 2016 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 362 increasing their positions, 351 reducing their positions, and 103 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 362 | Existing positions reduced: 351
7% less call options, than puts
Call options by funds: $1.05B | Put options by funds: $1.13B
8% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 103
2% less funds holding
Funds holding: 970 → 948 (-22)
14% less funds holding in top 10
Funds holding in top 10: 37 → 32 (-5)
16% less capital invested
Capital invested by funds: $59.1B → $49.9B (-$9.24B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$465M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$150M |
| 3 |
Primecap Management
Pasadena,
California
|
+$115M |
| 4 |
VAM
Visium Asset Management
New York
|
+$101M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$90.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$164M |
| 2 |
State Street
Boston,
Massachusetts
|
-$141M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$139M |
| 4 |
JP Morgan Chase
New York
|
-$137M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$101M |
BIIB Hedge Fund Activity: Q1 2016 in Review
948 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2016, worth a combined $49.9B — down 16% from $59.1B a quarter earlier.
Sellers outnumbered buyers: 103 funds closed out of BIIB and 95 opened new positions — a net loss of 8 holders — while 351 trimmed existing stakes and 362 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $465M. The largest seller was Wellington Management Group, cutting an estimated $164M.
- 948 institutional investors held Biogen (BIIB) as of Q1 2016, down from 970 in Q4 2015.
- Funds reported $49.9B of Biogen stock for Q1 2016, down 16% quarter-over-quarter.
- 95 funds opened new Biogen positions in Q1 2016 and 103 closed out, a net change of -8 holders.
- The largest Biogen buyer in Q1 2016 was T. Rowe Price Associates, an estimated $465M added.
- The largest Biogen seller in Q1 2016 was Wellington Management Group, an estimated $164M sold.
Based on aggregated 13F filings for Q1 2016.